Quick Answer
Telomir Pharmaceuticals, Inc. reported R&D Expense of $2.44 million for fiscal year 2025.
Telomir Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.44M | +9.0% |
| 2024 | $2.24M | +42.0% |
| 2023 | $1.57M | +88.9% |
| 2022 | $833.2K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $759.5K | +21.1% | +1673.0% |
| June 30, 2025 | $42.8K | -92.8% | -87.3% |
| March 31, 2025 | $337.0K | -58.1% | -46.3% |
| September 30, 2024 | $627.4K | +139.0% | +5.5% |
| June 30, 2024 | $594.8K | -10.9% | -26.0% |
| March 31, 2024 | $804.0K | +82.6% | +206.2% |
| September 30, 2023 | $262.6K | — | -60.7% |
| June 30, 2023 | $667.6K | — | +51.6% |
- Telomir Pharmaceuticals, Inc. showed an increase of +9.0% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Telomir Pharmaceuticals, Inc.’s r&d expense has grown by 192.3% (from $833.2 thousand to $2.44 million).
- The most recent figure is from Telomir Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: